Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Joseph L Gatuz"'
Autor:
Hyun Lee, Tian Zhu, Kavankumar Patel, Yan-Yan Zhang, Lena Truong, Kirk E Hevener, Joseph L Gatuz, Gitanjali Subramanya, Hyun-Young Jeong, Susan L Uprichard, Michael E Johnson
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e75144 (2013)
Development of drug-resistant mutations has been a major problem with all currently developed Hepatitis C Virus (HCV) NS3/4A inhibitors, including the two FDA approved drugs, significantly reducing the efficacy of these inhibitors. The high incidence
Externí odkaz:
https://doaj.org/article/865643715fb8455293491e77012d45c1
Autor:
Michael Z. Szypulinski, Michael E. Johnson, Hyun Lee, Kavankumar Patel, Joseph L. Gatuz, Isabel Ojeda, Hao Lei, Shuyi Cao, Bernard D. Santarsiero, Amy J. Rice, Arun K. Ghosh
Publikováno v:
ACS Chemical Biology
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) papain-like protease (PLpro) blocking loop 2 (BL2) structure differs significantly from that of SARS-CoV PLpro, where it has been proven to play a crucial role in SARS-CoV PLpro inhibitor bi
Autor:
Joseph L. Gatuz, Michael E. Johnson, Shuyi Cao, Arun K. Ghosh, Kavankumar Patel, Kirk E. Hevener, Lena Truong, Hyun Lee
Publikováno v:
ChemMedChem
We have previously developed two potent chemical classes that inhibit the essential papain-like protease (PLpro) of severe acute respiratory syndrome coronavirus (SARS-CoV). In this study, we applied a novel approach to identify small fragments that
Autor:
Hyun Lee, Debbie C. Mulhearn, Lena Truong, Jaime Torres, Joseph L. Gatuz, Anuradha Mittal, Kavankumar Patel, Michael E. Johnson
Publikováno v:
Bioorganic & Medicinal Chemistry
We have used a combination of virtual screening (VS) and high-throughput screening (HTS) techniques to identify novel, non-peptidic small molecule inhibitors against human SARS-CoV 3CLpro. A structure-based VS approach integrating docking and pharmac
Autor:
Hyunyoung Jeong, Yan-Yan Zhang, Lena Truong, Susan L. Uprichard, Tian Zhu, Gitanjali Subramanya, Michael E. Johnson, Kavankumar Patel, Joseph L. Gatuz, Hyun Lee, Kirk E. Hevener
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 10, p e75144 (2013)
PLoS ONE, Vol 8, Iss 10, p e75144 (2013)
Development of drug-resistant mutations has been a major problem with all currently developed Hepatitis C Virus (HCV) NS3/4A inhibitors, including the two FDA approved drugs, significantly reducing the efficacy of these inhibitors. The high incidence